Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE), Tuesday announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib in patients with locally advanced or metastatic estrogen receptor positive/human epidermal growth factor receptor 2 negative breast cancer.
The findings revealed that the combination of Aabemaciclib 150 mg twice daily with the recommended Phase 3 monotherapy dose of 200 mg of Vepdegestrant once daily was safe and well-tolerated in the participants. Moreover, it showed no significant drug-drug interaction, and no clinically meaningful effect on Abemaciclib exposure.
The companies added that the combination therapy demonstrated a clinical benefit rate of 62.5 percent, and overall response rate of 26.7 percent in patients previously treated with a CDK4/6 inhibitor.
Currently, Arvinas's stock is falling 1.75 percent, to $24.64 on the Nasdaq, while Pfizer's stock is trading at $25.81, down 1.13 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.